From The Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We report the cloning of a novel human activator
of c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase
kinase 7 (MKK7). The mRNA for MKK7 is widely expressed in humans
and mice and encodes a 47-kDa protein (419 amino acids), as determined by immunoblotting endogenous MKK7 with an antibody raised against its N
terminus. The kinase domain of MKK7 is closely related to a
Drosophila JNK kinase dHep (69% identity) and to a newly
identified ortholog from Caenorhabditis elegans (54%
identity), and was more distantly related to MKK4, MKK3, and MKK6. MKK7
phosphorylated and activated JNK1 but failed to activate p38 MAPK in
co-expression studies. In hematopoietic cells, endogenous MKK7 was
activated by treatment with the growth factor interleukin-3 (but not
interleukin-4), or by ligation of CD40, the B-cell antigen receptor, or
the receptor for the Fc fragment of immunoglobulin. MKK7 was also
activated when cells were exposed to heat, UV irradiation, anisomycin,
hyperosmolarity or the pro-inflammatory cytokine tumor necrosis
factor-. Co-expression of constitutively active mutants of RAS, RAC,
or CDC42 in HeLa epithelial cells or of RAC or CDC42 in Ba/F3
factor-dependent hematopoietic cells also activated MKK7,
suggesting that MKK7 will be involved in many physiological
pathways.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The responses of eukaryotic cells to extracellular stimuli are remarkably well conserved in evolution. In mammalian cells most extracellular stimuli result in the activation of three families of Ser/Thr protein kinases, the mitogen-activated protein kinases (MAPK)1 (1, 2). The extracellular-regulated kinases (ERK) MAPK are activated in response to growth factors including EGF and hematopoietic growth factors (1, 3). Members of the other two major families of MAP kinases, the c-Jun N-terminal kinases (JNK)/stress-activated protein kinases (SAPK) and the p38 MAP kinases, are strongly activated in response to stresses such as heat, UV light, anisomycin, or hyperosmolarity (4-8). However, recent work has shown that members of both families of stress-activated protein kinases are also activated by hematopoietic growth factors such as IL-3, GM-CSF, Steel locus factor, erythropoietin, granulocyte colony-forming factor (9-13), as well as by ligation of immunoregulatory molecules such as the antigen receptors of B and T lymphocytes, the Fc receptors of myeloid cells, CD40 or Fas (14-18).
MAP kinases are activated by dual specificity MAPK kinases (MKK) through phosphorylation of the threonine and tyrosine residues of a TXY motif present in their activation loops (subdomain VIII). Kinases of the JNK/SAPK family are characterized by a TPY activation motif (5, 6) and are activated by an MKK termed MKK4 or SEK1 (19-21). Several lines of evidence point to the existence of another MKK capable of activating the JNK/SAPK family. Moriguchi et al. (22) identified at least one JNK/SAPK kinase activity in addition to the activity of MKK4 in rat fibroblastic 3Y1 cells stimulated by hyperosmotic shock. Similarly Meier et al. (23) identified two JNK/SAPK kinase activities operationally termed SAPK kinase-4 and SAPK kinase-5 in KB cells, a human oral carcinoma cell line, following treatment with hyperosmolarity or anisomycin. The generation of embryonic stem (ES) cells in which the mkk4 gene was disrupted provided conclusive evidence for the existence of another JNK kinase, as ES cells lacking MKK4 still exhibited increased JNK activity following treatment with hyperosmolarity or UV irradiation (24, 25).
We now report the molecular cloning and characterization of a novel
human MKK (MKK7) and the identification of its ortholog in
Caenorhabditis elegans (cMKK7). The mRNA for MKK7 was
widely expressed and encodes a 419-amino acid protein that is most
highly related to the Drosophila MKK known as dHep (26).
MKK7 was capable of phosphorylating and activating JNK1 both in
vivo and in vitro but was unable to activate p38 MAPK
in vivo. MKK7 was activated in response to the hematopoietic
growth factor interleukin-3 (IL-3) or ligation of three receptors
involved in immune regulation as follows: CD40, the receptor for the Fc
fragment of immunoglobulin G (FcR), or the B-cell antigen receptor
(BCR), as well as by stresses such as hyperosmolarity, heat shock, UV
irradiation, anisomycin, or the pro-inflammatory cytokine tumor
necrosis factor- (TNF-
). Co-expression of MKK7 with
constitutively active mutants of the small GTPases RAS, RAC, or CDC42
indicated that MKK7 was downstream of RAS, RAC, or CDC42 in HeLa cells
and downstream of RAC or CDC42 in Ba/F3 cells.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Molecular Cloning of MKK7--
An expressed sequence tag (EST)
clone (aa 019720) containing the 3' end (464 bp) of MKK7 was identified
by screening the EST data base (University of Washington-Merck EST
project) with a degenerate oligonucleotide sequence based on homology
between other MKK (aa
F(X)6F(X)6CLXK(X)4R(X)8H).
We used oligonucleotide primers based on this MKK7 sequence to amplify
the 5' end of the kinase from a human fetal kidney rapid amplification
of cDNA ends cDNA library using Vent DNA polymerase for
polymerase chain reaction (PCR). All PCR products were subcloned, and
all colonies were transferred onto nitrocellulose and Southern blotted
with the EST fragment that had been radiolabeled by random priming. We used this technique to obtain a further 861 bp of MKK7 that
contained an in-frame stop codon and a splice variant of MKK7
(hMKK7
). The cDNA encoding full-length MKK7
was cloned from
at least two separate PCR reactions and was sequenced on both strands.
We used degenerate primers based on the human sequence to amplify the murine cDNA from Ba/F3 hematopoietic cell cDNA. The EST data
base was screened to identify a different splice variant of murine MKK7
(mMKK7
). Published data bases were screened for MKK related to MKK7
using the National Center for Biotechnology Information Advanced BLAST
search program.
cDNA Constructs-- Human MKK7 was amplified by PCR using primers to add an in-frame BamHI site to its 5' end to allow subcloning into pEFBOS-Nmyc3 and pEPG vectors. The vectors encoding pEPG-JNK1 and pEPG-SEK1 were the gifts of Dr. L. Zon. The mammalian expression vector encoding Flag-tagged CSBP2/p38 MAPK was given by Dr. Peter Young. The vectors encoding constitutively active RASLys-61, RACVal-12, and CDC42Val-12 were received from Dr. R. Kay, Dr. F. McCormick, and Dr. R. Cerione, respectively. The prokaryotic expression vector for GST-JNK1 was produced from pEPG-JNK1 by restriction digestion with BamHI and NotI followed by subcloning the cDNA encoding JNK1 into the polylinker of pGEX4T-3.
Recombinant Proteins and Antibodies--
GST-JNK1 and
GST-c-Jun-(1-169) were expressed in Escherichia coli
(UT5600 strain) and were purified by affinity chromatography on
glutathione-Sepharose beads (Amersham Pharmacia Biotech). The anti-p38
MAP kinase polyclonal antibody used for Western blotting (sc-535), the
anti-MKK4 polyclonal antibody (sc-964), and ATF-2 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The monoclonal antibody used
to cross-link CD40 (IC10) was a gift of Dr. M. Howard, and the sheep
anti-mouse F(ab)2 against the µ-chain of the B-cell
antigen receptor (BCR) was purchased from Jackson ImmunoResearch (West
Grove, PA). The antibody 2.4G2 (-FcR) that binds to and blocks the
Fc
receptor II and III without inducing signaling was purchased from
PharMingen (San Diego, CA), and the polyclonal rabbit anti-rat Ig
antibody (
-Ig) used for cross-linking the
-FcR antibodies on the
cell surface to induce FcR-mediated signaling was a gift of Dr. H. Ziltener (Vancouver, British Columbia, Canada). The M2 (
-Flag)
monoclonal antibody was obtained from Intersciences (Markham, Ontario).
Rabbit polyclonal antibodies recognizing MKK7 were raised against
peptides corresponding to the N terminus (aa 4-26) and the C terminus
(aa 394-413) of MKK7
, and both were fused at their N termini to the
T-cell epitope from tetanus toxin (27). Anti-MKK7 antibodies were
purified from serum of immunized rabbits using protein A-Sepharose.
Immunoblotting procedures were performed as described previously (9,
10).
Analysis of MKK7 Expression-- A Northern blot of mRNA from multiple human tissues was purchased from CLONTECH. The blot was hybridized with a probe from the 5' end of MKK7 (1-600 bp) that was radiolabeled by random priming. Hybridization and washing were performed according to manufacturer's specifications, and the mRNA encoding MKK7 was visualized using autoradiography. To investigate the expression of mRNA encoding MKK7, total RNA was isolated from a number of human and murine cell lines using Trizol (Life Technologies, Inc.) and reverse-transcribed using Moloney murine leukemia virus reverse transcriptase and an antisense oligonucleotide (5'-GTCATAGTCCGGCTT) present in the cDNA of both human and murine MKK7. A fragment of MKK7 was amplified by PCR using Taq DNA polymerase and the primers (sense, 5'-GCGCTACCAGGCAGA; antisense, 5'-TGCCATGAGCTCCAT) and was verified by nucleotide sequencing or restriction digestion.
Cell Culture and Transfection Conditions-- The IL-3-dependent cell lines Ba/F3 and MC/9 were cultured in RPMI 1640 supplemented with 10% fetal calf serum, 10 µM 2-mercaptoethanol, and 2% WEHI-3B conditioned medium as a source of IL-3. HeLa cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 10 µM 2-mercaptoethanol. The B-cell lymphoma cell line WEHI-231 was cultured in RPMI 1640 supplemented with 10% fetal calf serum and 10 µM 2-mercaptoethanol. Ba/F3 cells (1-1.5 × 107/sample) were transiently transfected with 15-25 µg of DNA using electroporation (300 V, 960 microfarads) in 400 µl of serum-free medium containing 10 µg/ml DEAE-dextran (Amersham Pharmacia Biotech). HeLa cells were transiently transfected using SuperFect reagent (Qiagen) according to the manufacturer's recommendations. Cells were harvested 20-24 h post-transfection as described below. Ba/F3 clones that stably expressed MKK7 were generated by co-electroporation of a vector encoding myc-tagged MKK7 (pEFBOS-mycMKK7) and a vector encoding a puromycin resistance gene (pGK-puro). Cells were plated in 96-well microtiter plates at 1.5 × 104 cells/well and selected in 1 µg/ml puromycin (Calbiochem). After 2 weeks, we observed 90 wells with drug-resistant clones. We selected 3 wells at random and recloned cells by limit dilution. Clones arising from each of these wells expressed readily detectable levels of myc-tagged MKK7 as determined by immunoblotting lysates with an anti-Myc monoclonal antibody 9E10 (Santa Cruz, CA).
Stimulation and Immunoprecipitation Conditions--
Prior to
stimulation, Ba/F3 or MC/9 cells were cultured in a 10-fold reduced
concentration of WEHI-3B conditioned medium (0.2%) for 16-20 h. Cells
were washed and equilibrated in serum-free RPMI 1640 buffered with 10 mM HEPES, pH 7.2, prior to stimulation. Cells were
stimulated with 0.2 M NaCl, 50 µg/ml anisomycin, 100 ng/ml TNF-, 100 ng/ml EGF, 10 µg/ml IC10, 40 µg/ml
-IgM
F(ab')2, or optimal doses of synthetic IL-3 or synthetic
IL-4 (10 µg/ml) for the indicated times. For FcR cross-linking, MC/9
mast cells were initially incubated with
-FcR for 10 min and then
were incubated for a further 10 min either untreated or with the
addition of a rabbit anti-rat Ig antibody to cross-link the
-FcR.
For UV irradiation, HeLa and Ba/F3 cells were exposed to a 30-watt UV light for 20 min in 60-mm dishes containing 1 ml of serum-free medium.
HeLa cells were heat-shocked by incubating for 20 min at 42 °C.
After stimulation, cells were lysed in solubilization buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 200 mM LiCl, 5 mM EDTA, 1% (v/v) Nonidet P-40, 1 mM sodium molybdate, 50 mM sodium
orthovanadate, 1 mM sodium fluoride, 50 mM
-glycerol phosphate, 10 µg/ml aprotinin, 10 µg/ml soybean
trypsin inhibitor, 0.7 µg/ml pepstatin, 2 µg/ml leupeptin, and 40 µg/ml phenylmethylsulfonyl fluoride). Samples for subsequent assays
were normalized for total protein using a Pierce protein assay or for
expression of transfected proteins by assaying co-transfected
-galactosidase activity. Proteins tagged with GST were
affinity-precipitated by incubating cellular extracts with 20 µl of a
50% slurry of glutathione-Sepharose beads for 1 h at 4 °C.
Endogenous MKK7 was immunoprecipitated using the rabbit polyclonal
antibody raised against the N terminus of MKK7, and endogenous MKK4 was
immunoprecipitated with an
-MKK4 antibody. Flag-tagged p38 MAPK was
immunoprecipitated using the M2 antibody and protein G-Sepharose.
Protein Kinase Assays--
Beads with associated kinases were
washed extensively with solubilization buffer and once with kinase
assay buffer (25 mM HEPES, pH 7.2, 25 mM
magnesium chloride, 2 mM dithiothreitol, 50 mM
-glycerol phosphate, and 0.5 mM sodium vanadate). MKK7 activity was measured directly by the ability of MKK7 to phosphorylate 1 µg of GST-JNK1 in the presence of an excess of free GST protein to
prevent the substrate from binding to the beads. MKK7 activity was also
assessed indirectly by first incubating MKK7 with 1 µg of GST-JNK1 in
the presence of 50 µM unlabeled ATP for 30 min and then
removing an aliquot and determining the activity of GST-JNK1 in an
in vitro kinase reaction using 1 µg of GST-c-Jun as
substrate. All kinase reactions were initiated by the addition of
kinase assay buffer containing the appropriate substrate and 10 µCi
of [
-32P]ATP and stopped after 20 min by the addition
of SDS-sample buffer. For p38 MAP kinase assays, Flag-tagged p38 MAPK
was immunoprecipitated using
-Flag antisera and protein G-Sepharose
beads. The beads were washed and kinase activity was assessed using
ATF-2 as a substrate. The only modification was the inclusion of an
additional unlabeled ATP (50 µM). Phosphorylated
proteins were visualized after SDS-PAGE by autoradiography.
Densitometry was performed using an HSI scanning densitometer.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Molecular Cloning of the cDNA of MKK7--
We screened the EST
(expressed sequence tags) data base using a degenerate oligonucleotide
sequence based on the amino acids conserved in the C terminus of all
previously characterized mitogen-activated protein kinase kinases (19).
We identified 10 clones that encoded known MKK family members and one
clone that contained a novel human sequence. This clone contained 464 base pairs (bp) of coding region and approximately 1200 bp of
3'-untranslated region. We used 5'-rapid amplification of cDNA ends
to isolate overlapping 5'-fragments of this novel cDNA from a human
fetal kidney rapid amplification of cDNA ends cDNA library
(CLONTECH). By using this technique we cloned a
further 861 bp of human MKK7 (hMKK7) that contained an in-frame stop
codon. When translation was initiated at the first methionine, this
cDNA encoded a 419-amino acid protein (Fig.
1A) that contained a putative
protein kinase domain. We also isolated a splice variant of human MKK7
(MKK7
) that contained an additional 126 base pairs encoding an
insert of 42 amino acids (Fig. 1A). We screened the yeast
and invertebrate data bases for other MKK related to MKK7, and although
we failed to identify a yeast homolog, we did find an ortholog of MKK7
in Drosophila melanogaster (dHep, 69% identity) (26). In
C. elegans we identified an ortholog with 54% identity we
termed cMKK7 (28). As seen in the radial dendrogram comparing the
catalytic domains of MKK7 with dHep, cMKK7, and all other known human
MKK (Fig. 1B), MKK7 was orthologous with dHep and cMKK7 and
was more closely related to these than to the known human MKK.
|
Expression and Tissue Distribution of MKK7--
To investigate
expression of endogenous and exogenous MKK7, we immunoblotted lysates
of MC/9 mast cells, Ba/F3 cells, and a clone of Ba/F3 cells that stably
expressed MKK7 (Ba/F3-MKK7) with an antiserum raised against the N
terminus of MKK7. We identified an immunoreactive protein of 47 kDa,
consistent with the size predicted from the cDNA of MKK7 or
MKK7
(Fig. 2A). Thus Ba/F3 and MC/9 cells expressed the N terminus predicted by translation of the
cDNA encoding mMKK7
or mMKK7
. We were unable to detect an
immunoreactive protein at the size (53 kDa) predicted to correspond to
the hMKK7
splice variant in murine cells. These experiments indicated that the levels of exogenous MKK7 expressed in Ba/F3-MKK7 cells were at least 30-fold greater than endogenous MKK7 (Fig. 2A). This was interesting as the Ba/F3-MKK7 cells exhibited
no obvious abnormalities in growth and remained dependent on IL-3 for
growth and survival. Moreover, overexpression of human MKK7 did not
appear to affect the expression of endogenous murine MKK7, as 5 × 105 cells of both untransfected and Ba/F3-MKK7 cells
expressed comparable levels of endogenous MKK7 (Fig.
2A).
|
|
Activation of JNK1, but Not p38, by MKK7-- It has been previously shown that the transient co-expression of mitogen-activated protein kinases with the appropriate upstream MKK leads to in vivo activation of the MAPK. We investigated the substrate specificity of MKK7 by co-expression of MKK7 with either JNK1 or p38 MAP kinase. Co-expression of MKK7 with JNK1 in HeLa epithelial cells (Fig. 3A) or Ba/F3 hematopoietic cells (data not shown) without any deliberate stimulation of the cells resulted in easily detectable activation of JNK1. Stimulation of these co-transfected cells with hyperosmotic shock (0.2 M NaCl) or UV light resulted in even greater JNK1 activation (Fig. 3A). These results suggested that MKK7 was upstream of JNK1 and was activated by stimulation of cells by UV light or hyperosmotic shock. In contrast, co-expression of p38 MAPK with MKK7 had no effect on activation of p38 MAPK (Fig. 3B). Nor did co-expression of MKK7 with p38 MAPK result in increased activation of p38 MAPK when the transfected cells were stimulated by hyperosmotic shock or UV light. Thus MKK7, unlike MKK4, specifically activated JNK1 but not p38 MAP kinase.
|
Transiently Expressed MKK7 Is Activated in Response to Multiple
Stimuli--
The c-Jun N-terminal kinases have been shown to be
activated in response to a number of different stimuli including UV
light, hyperosmotic shock, protein synthesis inhibitors, heat shock, the pro-inflammatory cytokines IL-1 and TNF-, and hematopoietic growth factors (4, 10). We tested the ability of these stimuli to
activate GST-MKK7 that had been transiently overexpressed in HeLa or
Ba/F3 cells. GST or GST-MKK7 was purified from extracts of cells
subjected to various stimuli, and its ability to phosphorylate GST-JNK1
was assessed in an in vitro kinase assay. As shown in Fig.
4A, the activity of MKK7 was
increased by treatment of cells with hyperosmotic shock (11-fold), heat
shock (7.5-fold), UV light (5.5-fold), or TNF-
(3.5-fold) but not by
EGF (Fig. 4A). The ability of these stimuli to activate MKK7
and to in turn activate JNK1 in vitro was also assessed. We
observed the ability of MKK7 to activate JNK1 was increased in
transfected cells treated with TNF-
(4-fold), hyperosmotic shock
(5-fold), or anisomycin (5-fold for 30 min; 6.5-fold for 45 min) (Fig.
4B). Thus MKK7 was activated by all these known activators
of JNK. We and others (10-12) have previously demonstrated the
activation of JNK in response to stimulation by the hematopoietic
growth factor IL-3 in both Ba/F3 hematopoietic cells and MC/9 mast
cells. In contrast, the related hematopoietic growth factor IL-4 failed
to activate JNK (10). We transiently expressed GST-MKK7 in Ba/F3 cells,
subjected them to various stimuli, and assayed the ability of MKK7,
which was activated in vivo, to phosphorylate GST-JNK1
in vitro. As seen in Fig. 4C, MKK7 was strongly
activated compared with the activity of MKK7 from unstimulated cells,
in cells treated with IL-3 (5.5-fold), 0.2 M NaCl
(4.5-fold), or UV light (3.5-fold). In contrast, MKK7 was not activated
in cells treated with IL-4 (Fig. 4C), correlating with its
inability to activate JNK (10).
|
Activation of Endogenous MKK4 and MKK7 by Various Physiological
Stimuli--
We next investigated the activation of endogenous MKK7 in
response to physiological stimuli. In parallel we also investigated the
activation of the known JNK activator MKK4 to identify potential functional differences. The antibodies used for immune complex kinase
assays specifically recognized MKK4 or MKK7 (Fig.
5A). We first examined the
ability of TNF- to activate MKK4 and MKK7 in HeLa cells. As seen in
Fig. 5B, we observed an increase in the activity of both
MKK4 (5-fold) and MKK7 (2.5-fold). We then examined the ability of
IL-3, IL-4, anisomycin, and 0.2 M NaCl to activate MKK7 in
Ba/F3 cells. Consistent with the results of experiments with
transiently expressed MKK7, cells treated with IL-3 exhibited an
increased activation (8-fold) of endogenous MKK7 (Fig. 5C).
Cells treated with IL-3 also exhibited an increase in MKK4 activity
(3-fold). In contrast, cells treated with IL-4 failed to activate MKK7
(Fig. 5C). Anisomycin and hyperosmotic shock also activated
endogenous MKK7 (4- and 14-fold).
|
MKK7 Activates JNK Downstream of RAS, RAC, and CDC42-- Expression of constitutively active mutants of the RAS and RHO family of small GTPases activates the JNK family of protein kinases (6, 7, 29-31). We confirmed that co-expression in HeLa cells of GST-JNK1 and RASLys-61, RACVal-12, or CDC42Val-12 activated the JNK pathway (data not shown). We then co-expressed GST-MKK7 with each of these mutant GTPases, affinity-precipitated the GST-MKK7, and assessed its ability to activate GST-JNK1 in vitro, using phosphorylation of GST-c-Jun as a readout of JNK1 activity. We found that co-expression of activated mutants of RAS, RAC, or CDC42 and MKK7 in HeLa cells resulted in marked activation of MKK7, demonstrating that this kinase could be activated by signals downstream of each of these GTPases (Fig. 6A). Similar results were obtained when GST-MKK4 was co-expressed with these GTPases in HeLa cells (Fig. 6A). We also performed similar experiments in the murine hematopoietic cell line Ba/F3. Co-expression of GST-JNK1 and the constitutively active mutants of RAC and CDC42 resulted in activation of JNK1 in Ba/F3 cells; however, co-expression of activated RAS with JNK1 resulted in little or no activation of JNK1 (data not shown). In keeping with these findings, co-expression of MKK7 and RAC or CDC42 in Ba/F3 cells activated MKK7; however, the co-expression of activated RAS with MKK7 was not sufficient to activate MKK7 (Fig. 6B).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our results indicate that human and murine MKK7 are highly conserved (99% identity) and are most closely related to dHep, a MKK in Drosophila, exhibiting 69% identity in the kinase domain. MKK7 was less related to MKK4, MKK6, or MKK3 (~45-55% identity), the other mammalian MKK known to be activators of JNK and p38 MAPK, and was even less similar to MEK1 or MEK2 (~30-35% identity), the activators of ERK MAPK (Fig. 1B). We conducted extensive searches of the yeast and invertebrate data bases, and although we failed to identify MKK7 in Saccharomyces cerevisiae, we did identify a highly related C. elegans MKK (cMKK7) that exhibited 54% identity to MKK7 within the kinase domain (28). A more detailed inspection of alignments revealed a series of residues or motifs that were conserved among dHep, MKK7, and cMKK7 that were not present in MKK3, MKK4, and MKK6, and vice versa. Particularly striking are differences in the activation loops, with MKK7, dHep, and cMKK7 being characterized by a basic amino acid (S(K/R)AKT), at the same position where in MKK3, MKK4, and MKK6 a hydrophobic residue (S(I/V)AKT) is found. Overall these patterns of conservation of specific motifs support the notion that MKK7 is orthologous with dHep and cMKK7 and is more distantly related to MKK4, MKK3, and MKK6 (Fig. 1B). It will be interesting to determine the functional significance of the conserved residues that characterize MKK7, dHep, and cMKK7 and distinguish them from MKK4, MKK3, and MKK6.
Tournier et al. (32) have recently reported the cloning of
two splice variants of murine MKK7 and the N terminus of human MKK7.
The amino acid sequence predicted from their murine MKK7a clone is
identical to the sequence that we report here, with the exception that
it lacks the N terminus that was present in all of our predicted human
and murine MKK7 splice variants. We were able to immunoblot endogenous
MKK7 in lysates of Ba/F3 hematopoietic cells and MC/9 mast cells using
an antiserum raised against the N terminus of our human and murine MKK7
sequence (Fig. 2A), and therefore we are confident that the
form of MKK7 predicted from our human and murine cDNA is indeed
expressed in murine cells.
Since submission of this manuscript there have been a number of
articles describing the cloning of MKK7 (33-38). Holland et al. (33) have identified two isoforms of murine MKK7, one
corresponding to murine MKK7 and the other with a unique N terminus.
Moriguchi et al. (34) have cloned murine MKK7
and
identified two MKK7 isoforms using an antiserum raised against
full-length murine MKK7
. Based on electrophoretic mobility, we
believe the larger isoform could represent the murine equivalent of our
human MKK7
(Fig. 1A). Lu et al. (35) have
identified another isoform of human MKK7 that has the same N terminus
and kinase domain as our MKK7 isoforms but contains 70 amino acids that
are unique to any of the MKK7 isoforms reported to date.
Based on sequence identities between the known MKK (Fig.
1B), we investigated the ability of MKK7 to activate JNK or
p38 MAPK and showed that in co-transfection assays MKK7 acted upstream of JNK1 (Fig. 3A) but not p38 MAPK (Fig. 3B). The
identification of JNK1 as an in vitro substrate for MKK7
permitted us to investigate the ability of a range of stimuli to
activate transiently expressed MKK7. In HeLa cells, MKK7 was strongly
activated by hyperosmotic shock, UV light, anisomycin, heat shock, and
to a lesser extent TNF- (Fig. 4, A and B). We
observed no detectable activation of MKK7 in HeLa cells treated with
EGF (Fig. 4A). These results are similar to that seen by
Holland et al. (33) with platelet-derived growth factor in
NIH3T3 cells. In Ba/F3 hematopoietic cells, hyperosmotic shock and UV
light also activated MKK7 (Fig. 4C). Our observations that
stimulation of Ba/F3 cells with IL-3 increased the activity of MKK7
(Figs. 4C and 5C) correlate with recent
observations that JNK was activated by a range of hematopoietic growth
factors including IL-3, granulocyte-macrophage colony-stimulating
factor, G-CSF, erythropoietin or Steel locus factor
(10-13). Moreover our observation that IL-4 failed to activate MKK7
(Figs. 4C and 5C) correlates with the inability
of IL-4 to activate the RAS, ERK, p38, or JNK MAP kinase pathways in
hematopoietic cells (3, 9-10, 39-40).
Co-expression of activated mutants of RAS, RAC, or CDC42 with MKK7 in HeLa cells resulted in readily detectable activation of MKK7 and MKK4 (Fig. 6A). This is consistent with previous work that demonstrated that the RAS and RHO family of small GTPases are capable of activating JNK (6, 7, 29-31). Slightly different results were obtained in Ba/F3 cells where MKK7 was activated by co-expression of activated RAC or CDC42 but not RAS (Fig. 6B). The inability of RAS to activate MKK7 was not surprising as a constitutively active RAS was insufficient to activate JNK in Ba/F3 cells (11), although IL-3-induced JNK activation was blocked by expression of a dominant-negative mutant of RAS (11). Taken together, these results support the notion that RAS is necessary but not sufficient for JNK activation. Our evidence that IL-3 increased MKK7 activity (Figs. 4C and 5C), but that RAS alone failed to increase MKK7 activity (Fig. 6B), is also consistent with data on activation of JNK by G-CSF, which is structurally related to IL-3 and acts through a similar receptor. These experiments showed that activation of JNK in cells stimulated with G-CSF depended upon both an intact RAS signaling pathway as well as a specific tyrosine residue in the G-CSF receptor (13). Together these data suggest that activation of MKK7 in response to IL-3 involves both activation of the RAS pathway and an as yet unknown signal.
Depending on differentiation of the B lymphocyte and the presence of co-stimulatory molecules such as CD40, signaling through the BCR can initiate signals for either growth and survival or death of the B lymphocyte (41). Previous studies have shown the BCR to be a weak activator of JNK (16). We observed that ligation of the µ-chain of the BCR on WEHI-231 cells induced weak, but reproducible, activation of MKK7 (Fig. 5D), consistent with the activation of JNK we observed after ligation of the BCR (data not shown).
The receptor for the Fc fragment of immunoglobulin G (FcR) is
structurally related to the BCR and has many important roles in the
immune system (42). These include the phagocytosis of Ig-coated
particles by macrophages and neutrophils, the
antibody-dependent cell-mediated cytotoxicity by NK cells,
the down-regulation of signaling through the BCR, and the release of
TNF- and other mediators by macrophages and mast cells. Our
observation that ligation of FcR results in the activation of both
endogenous MKK4 and MKK7 in MC/9 mast cells (Fig. 5E)
supports previous findings that signaling through the FcR activates JNK
in bone marrow-derived macrophages (17). Recent studies have shown that
signaling through the JNK pathway is required for the production of
TNF-
in MC/9 mast cells (43). As signaling through the FcR activates
JNK through MKK4 and MKK7, it will be important to determine their individual roles in the production of TNF-
in mast cells.
CD40 is a member of the TNF receptor family, and ligation of CD40 has
been reported to activate JNK in B-cells (15, 16). Signaling through
CD40 is critical for the growth, differentiation, and class switching
of B lymphocytes (44), and the development of the Th1 subset of T
lymphocytes through the activation of macrophages and dendritic cells
(45). Our findings that ligation of CD40 activated both endogenous MKK4
and MKK7 (Fig. 5D) is consistent with our findings on the
activation of endogenous MKK4 and MKK7 in HeLa cells treated with
TNF- (Fig. 5B). MKK7 has also been reported to be
activated by ligation of Fas, another member of the TNF receptor family
(46). Together these findings suggest that activation of MKK7 may be a
common feature of signals activated by ligation of members of the TNF
receptor family. Recent reports have shown that the genetic disruption
of mkk4 in B lymphocytes failed to affect their growth or
their ability to undergo class switching (47). It will be interesting
to determine the role of MKK7 in the physiological regulation of the
immune system via signaling through the BCR, the FcR, or CD40.
The existence of multiple activators of JNK responsive to different
stimuli was established by the fact that MKK4-deficient ES cells still
exhibited activation of JNK in response to hyperosmolarity and UV light
but not heat shock or anisomycin (19-20). In that MKK7 is activated by
all of the above stimuli (Figs. 4 and 5), and MKK7 mRNA is present
in ES cells (Table I), the failure of MKK4-deficient ES cells to
activate JNK in response to heat shock or anisomycin is paradoxical. It
is possible that, although MKK7 is expressed in ES cells, it is not
activated by heat or anisomycin because of cell-specific differences in
upstream activators. This notion is supported by a recent report that
in KB and U937 cells TNF- activates MKK7 but not MKK4 (34, 37),
whereas in HeLa cells we observed that TNF-
activates both MKK7 and
MKK4 (Fig. 5B), an observation recently reported by Wu
et al. (36). MKK4 has also been recently reported to be
activated in normal bone marrow-derived macrophages treated with
TNF-
, supporting the notion that these kinases will be regulated
differently depending on their cellular context (48). Furthermore, Wu
et al. (36) have reported that ASK1 and GCK activate MKK7 in
preference to MKK4, whereas MEKK1 and MEKK2 activate both MKK4 and MKK7
to comparable levels.
The functional significance of the activation of MKK7 is unclear, but its activation by physiological stimuli such as IL-3 (Figs. 4C and 5C), by ligation of immunoregulators such as CD40 (Fig. 5D), BCR (Fig. 5D), FcR (Fig. 5E), CD3 (36),2 or by the GTPases RAS, RAC, and CDC42 (Fig. 6) suggest that the role of MKK7 will not be confined to stress responses. The existence of an ortholog of MKK7 in C. elegans and our failure to identify an ortholog in S. cerevisiae suggest that MKK7 arose in evolution during the transition from single cellular to multicellular organisms. The notion that MKK7 is involved in processes important for multicellular organisms such embryonic development, chemotaxis, or apoptosis is in keeping with evidence that mutations in dHep and Bsk, the Drosophila homolog of JNK1, result in a similar failure of epithelial cell movement and dorsal closure (26, 49, 50). Holland et al. (33) have demonstrated that MKK7 is able to partially complement a deficiency of dHep in Drosophila. This demonstrates that MKK7 is highly conserved functionally and suggests that it may play a role in embryological development in mammals. The embryonic lethality resulting from disruption of the mkk4 gene in mice also points to the importance of normal JNK signaling during embryonic development (24-25) and indicates that MKK4 and MKK7 have discrete physiological functions. Future work detailing the function of individual activators of JNK is likely to reveal roles in multiple aspects of development and other physiological processes, including hematopoiesis and immune responses.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank I. Clark-Lewis for synthesizing cytokines and the peptides used for antibody production; H. Ziltener for the rabbit anti-rat immunoglobulin antibody (R108); M. Howard for IC10; P. Young for Flag-tagged CSBP2; L. Zon for the pEPG expression constructs of JNK1 and SEK1; R. Kay for RASLys-61; R. Cerione for CDC42Val-12; and F. McCormick for RACVal-12. We thank K. Leslie for sharing identification of the MKK from C. elegans; M. Levings for helpful discussions; and F. Lee for excellent technical assistance.
![]() |
FOOTNOTES |
---|
* This work was supported in part by the Medical Research Council of Canada.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) hMKK7, AF013588; hMKK7
, AF013589; mMKK7
, AF022112; and mMKK7
, AF022113.
Supported by a Medical Research Council Studentship.
§ To whom correspondence should be addressed. Tel.: 604-822-7813; Fax: 604-822-7815; E-mail: john{at}brc.ubc.ca.
1
The abbreviations used are: MAPK,
mitogen-activated protein kinase; IL, interleukin; TNF-, tumor
necrosis factor-
; FcR, Fc receptor for IgG; BCR, B-cell antigen
receptor; MAP, mitogen-activated protein; MKK, MAP kinase kinase; JNK,
c-Jun N-terminal kinase; SAPK, stress-activated protein kinase; ATF-2,
activating transcription factor-2, GST, glutathione
S-transferase; ES, embryonic stem; PAGE, polyacrylamide gel
electrophoresis; EGF, epidermal growth factor; PCR, polymerase chain
reaction; bp, base pair(s); aa, amino acid(s); EST,
expressed-sequence tag; G-CSF, granulocyte colony-stimulating
factor.
2 M. Luckach and R. Salmon, unpublished observations.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|